Shennon's fully integrated technology platform is redefining TCE development. We have identified novel targets, screened binders, and evaluated potential on-target and off-target toxicity for clinical safety.
With this, we are working on a pipeline of first-in-class and/or best-in-class drugs against various solid tumor indications.
Program
Indication
Discovery
Preclinical
Clinical
SBT 2611
Solid tumor
Solid tumor
Solid tumor
SBT 2612
SBT 2613
UNdisclosed
Autoimmunity
Program
SBT 2611
Indication - Solid tumor
Phase - Preclinical
Program
SBT 2612
Indication - Solid tumor
Phase - Preclinical
Program
SBT 2613
Indication - Solid tumor
Phase - Preclinical
Program
UNdisclosed
Indication - Autoimmunity
Phase - Discovery
Shennon Biotechnologies Inc.
2325 3rd Street, Suite 327-328, San Francisco, CA 94107
info@shennonbio.com